Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report Second Quarter 2017 Results on August 7th

Read More

Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330

Read More

Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range